Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Centre, West China Hospital, Sichuan University, Chengdu, China.
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):323-330. doi: 10.1016/j.bbcan.2019.02.004. Epub 2019 Feb 28.
The combination of programmed cell death 1/programmed cell death ligand 1 blockade and thoracic radiotherapy has become the new standard of care in the treatment of locally advanced non-small-cell lung cancer. The information regarding the pulmonary safety of such therapy remains limited to mostly retrospective studies and case reports with a small portion of data from prospective clinical trials. By analyzing the underlying mechanisms of interactions between radiation and immunotherapy from preclinical data and summarizing safety data from relevant clinical studies with pulmonary toxicity, we believe that longer and rigorous follow-up is warranted, to determine if the combination of such modalities is appropriate for patients without risking undue toxicity.
程序性细胞死亡蛋白 1/程序性细胞死亡配体 1 阻断与胸部放疗的联合治疗已成为局部晚期非小细胞肺癌治疗的新标准。关于这种治疗方法肺部安全性的信息主要局限于回顾性研究和病例报告，只有一小部分来自前瞻性临床试验的数据。通过分析临床前数据中放射治疗与免疫治疗相互作用的潜在机制，以及对具有肺毒性的相关临床研究的安全性数据进行总结，我们认为需要进行更长时间和更严格的随访，以确定这些治疗方法的联合应用是否适合患者，而不会带来不必要的毒性。
